What is Calquence
Approved as Treatment by the FDAAcalabrutinib, otherwise called Calquence, is approved by the FDA for 4 uses like Mantle Cell Lymphoma and ≥ 1 prior therapy for Mantle cell lymphoma .
When to interrupt dosageThe recommended measure of Calquence is contingent upon the diagnosed state, for instance Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma. The dosage likewise changes in accordance to the administration technique (e.g. Oral or Capsule) stated in the table hereunder.
WarningsThere are 20 known major drug interactions with Calquence.
Calquence Novel Uses: Which Conditions Have a Clinical Trial Featuring Calquence?338 active trials are being conducted to investigate the potential of Calquence in alleviating Mantle Cell Lymphoma, ≥ 1 prior therapy for Mantle cell lymphoma and Small Lymphocytic Lymphoma.
Calquence Reviews: What are patients saying about Calquence?
Patient Q&A Section about calquenceThese questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What kind of drug is Calquence?
"Acalabrutinib is a medication used to treat certain types of cancer, such as [mantle cell lymphoma](https://www.withpower.com/clinical-trials/mantle-cell-lymphoma), small lymphocytic lymphoma (SLL), and chronic lymphocytic leukemia (CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors."
Is Calquence considered chemotherapy?
"CALQUENCE can be used as a targeted alternative to traditional chemotherapy for patients with CLL/SLL who have already received another treatment. CALQUENCE is a kinase inhibitor that affects the growth of CLL/SLL cancer cells."
How effective is Calquence?
"In the final analysis of ASCEND, an estimated 82% of patients with relapsed or refractory CLL treated with Calquence remained alive and free from disease progression at 18 months compared with only 48% of patients on rituximab combined with idelalisib or bendamustine."